Research Article
CT-Guided Percutaneous Microwave Ablation of Sclerosing Hepatic Carcinoma
Table 2
Demographics of 137 patients with SHC.
| | | NTMSWA | Surgery | Comparison value |
| | Age | | | 0.4869 | | <65 | 72 (75%) | 33 (80.5%) | | ≥65 | 24 (25%) | 8 (19.5%) |
| | Sex | | | 0.2908 | | M | 33 (34.4%) | 18 (33.9%) | | F | 63 (65.6%) | 23 (56.1%) |
| | HV infection | | | 0.3405 | | HBV | 30 (31.3%) | 15 (36.6%) | | HBV + alcohol use | 57 (59.4%) | 25 (71%) | | HCV | 9 (9.4%) | 1 (2.4%) |
| | Hepatic cirrhosis | | | 0.3751 | | Positive | 87 (90.6%) | 39 (95.1%) | | Negative | 9 (9.4%) | 2 (4.9%) |
| | Tumor size (mm) | Mean 24.7 mm | Mean 26.5 mm | 0.3541 | | <30 | 75 (78.1%) | 29 (70.7%) | | 30–50 | 21 (21.9%) | 12 (29.3%) |
| | Tumor location | | | 0.5426 | | Right lobe | 66 (68.8%) | 26 (63.4%) | | Left lobe | 30 (31.3%) | 15 (36.6%) |
| | AFP (μg/L) | | | 0.8767 | | ≤200 | 69 (71.9%) | 30 (73.2%) | | >200 | 27 (28.1%) | 11 (26.8%) | | ALT (IU/L) | 33.5 ± 18.6 | 29.4 ± 16.5 | 0.2243 | | AST (IU/L) | 34.2 ± 14.7 | 31.2 ± 12.7 | 0.2574 | | Platelet count (109/L) | 132.5 ± 62.5 | 157 ± 77.2 | 0.0527 |
| | Total bilirubin (μmol/L) | | | 0.1324 | | <34 | 30 (31.3%) | 16 (39.1%) | | 34–50 | 66 (68.8%) | 25 (60.9%) |
| | Albumin (g/L) | | | 0.7089 | | >35 | 60 (62.5%) | 27 (65.9%) | | 28–35 | 36 (37.5%) | 14 (34.1%) |
| | Child-Pugh score | | | <0.001 | | A | 27 (28.1%) | 30 (73.2%) | | B | 69 (71.9%) | 11 (26.8%) |
| | BCLC staging | | | 0.5426 | | A | 30 (31.3%) | 15 (36.6%) | | B | 66 (68.8&) | 26 (63.4%) |
| | Histologic type | | | 0.2219 | | BDA | 60 (62.5%) | 21 (51.2%) | | ICC | 27 (28.1%) | 12 (29.3%) | | HCC | 9 (9.4%) | 8 (19.5%) |
|
|
BDA, bile duct adenocarcinoma; ICC, intrahepatic cholangiocarcinoma; HCC, hepatocellular carcinoma.
|
